Mitogenic insulin receptor-A is overexpressed in human hepatocellular carcinoma due to EGFR-mediated dysregulation of RNA splicing factors

Cancer Research

Volumn 73, Issue 13, 2013, Pages 3974-3986

  Chettouh, Hamza ^a,b   Fartoux, Laetitia ^a,b,c   Aoudjehane, Lynda ^a,b,c   Wendum, Dominique ^a,b,c   Clapéron, Audrey ^a,b   Chrétien, Yves ^a,b   Rey, Colette ^a,b   Scatton, Olivier ^a,b,c   Soubrane, Olivier ^a,b,c   Conti, Filomena ^a,b,c   Praz, Fraņcoise ^a,b   Housset, Chantal ^a,b   Rosmorduc, Olivier ^a,b,c   Desbois Mouthon, Christèle ^a,b  

^a CENTRE DE RECHERCHE SAINT ANTOINE   (France)

^b SORBONNE UNIVERSITÉ   (France)

^c HÔPITAL SAINT ANTOINE   (France)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; INSULIN RECEPTOR; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE; RNA; SMALL INTERFERING RNA;

ALTERNATIVE RNA SPLICING; ANIMAL CELL; ANIMAL TISSUE; ARTICLE; AUTOCRINE EFFECT; CANCER RISK; CONTROLLED STUDY; GENE EXPRESSION; HUMAN; HUMAN CELL; HUMAN TISSUE; HYPERINSULINEMIA; IMMUNOFLUORESCENCE; LIVER CELL; LIVER CELL CARCINOMA; LIVER RESECTION; MAJOR CLINICAL STUDY; MALIGNANT TRANSFORMATION; NONHUMAN; PARACRINE SIGNALING; PARTIAL HEPATECTOMY; PRIORITY JOURNAL; RAT; RNA INTERFERENCE; RNA ISOLATION; RNA SPLICING;

ANIMALS; ANTIGENS, CD; CARCINOMA, HEPATOCELLULAR; CELL TRANSFORMATION, NEOPLASTIC; GENE EXPRESSION; GENE EXPRESSION REGULATION, NEOPLASTIC; HEP G2 CELLS; HEPATOCYTES; HETEROGENEOUS-NUCLEAR RIBONUCLEOPROTEIN GROUP A-B; HUMANS; INSULIN; INSULIN-LIKE GROWTH FACTOR II; LIVER NEOPLASMS, EXPERIMENTAL; LIVER REGENERATION; MAP KINASE SIGNALING SYSTEM; NUCLEAR PROTEINS; PROTEIN ISOFORMS; RATS; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTOR, INSULIN; RNA SPLICING; RNA, MESSENGER; RNA-BINDING PROTEINS;

EID: 84880065929     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-12-3824     Document Type: Article

References (50)

1. Renehan AG, Frystyk J, Flyvbjerg A. Obesity and cancer risk: the role of the insulin-IGF axis. Trends Endocrinol Metab 2006;17: 328-36.
2. Gallagher EJ, LeRoith D. The proliferating role of insulin and insulinlike growth factors in cancer. Trends Endocrinol Metab 2010;21: 610-8.
3. Pollak M. The insulin and insulin-like growth factor receptor family in neoplasia: an update. Nat Rev Cancer 2012;12: 159-69.
4. Belfiore A, Malaguarnera R. Insulin receptor and cancer. Endocr Relat Cancer 2011;18: R125-47.
5. Shaw LM. The insulin receptor substrate (IRS) proteins: at the intersection of metabolism and cancer. Cell Cycle 2011;10: 1750-6.
6. Nkontchou G, Bastard JP, Ziol M, Aout M, Cosson E, Ganne-Carrie N, et al. Insulin resistance, serum leptin, and adiponectin levels and outcomes of viral hepatitis C cirrhosis. J Hepatol 2010;53: 827-33.
7. Chao LT, Wu CF, Sung FY, Lin CL, Liu CJ, Huang CJ, et al. Insulin, glucose and hepatocellular carcinoma risk in male hepatitis B carriers: results from 17-year follow-up of a population-based cohort. Carcinogenesis 2011;32: 876-81.
8. Donadon V, Balbi M, Valent F, Avogaro A. Glycated hemoglobin and antidiabetic strategies as risk factors for hepatocellular carcinoma. World J Gastroenterol 2010;16: 3025-32.
9. Hassan MM, Curley SA, Li D, Kaseb A, Davila M, Abdalla EK, et al. Association of diabetes duration and diabetes treatment with the risk of hepatocellular carcinoma. Cancer 2010;116: 1938-46.
10. SpectorSA, Olson ET, Gumbs AA, Friess H, BuchlerMW,Seymour NE. Human insulin receptor and insulin signaling proteins in hepatic disease. J Surg Res 1999;83: 32-5.
11. Boissan M, Beurel E, Wendum D, Rey C, Lecluse Y, Housset C, et al. Overexpression of insulin receptor substrate-2 in human and murine hepatocellular carcinoma. Am J Pathol 2005;167: 869-77.
12. Tanaka S, Wands Jr. Insulin receptor substrate 1 overexpression in human hepatocellular carcinoma cells prevents transforming growth factor beta1-induced apoptosis. Cancer Res 1996;56: 3391-4.
13. Belfiore A, Frasca F, Pandini G, Sciacca L, Vigneri R. Insulin receptor isoforms and insulin receptor/insulin-like growth factor receptor hybrids in physiology and disease. Endocr Rev 2009;30: 586-623.
14. Breuhahn K, Schirmacher P. Reactivation of the insulin-like growth factor-II signaling pathway in human hepatocellular carcinoma. World J Gastroenterol 2008;14: 1690-8.
15. Knudsen L, De Meyts P, Kiselyov VV. Insight into the molecular basis for the kinetic differences between the two insulin receptor isoforms. Biochem J 2011;440: 397-403.
16. Sen S, Talukdar I, Webster NJ. SRp20 and CUG-BP1 modulate insulin receptor exon 11 alternative splicing. Mol Cell Biol 2009;29: 871-80.
17. Berasain C, Goni S, Castillo J, Latasa MU, Prieto J, Avila MA. Impairment of pre-mRNA splicing in liver disease: mechanisms and consequences. World J Gastroenterol 2010;16: 3091-102.
18. Zhou Z, Qiu J, Liu W, Zhou Y, Plocinik RM, Li H, et al. The Akt-SRPK-SR axis constitutes a major pathway in transducing EGF signaling to regulate alternative splicing in the nucleus. Mol Cell 2012;47: 422-33.
19. Savkur RS, Philips AV, Cooper TA. Aberrant regulation of insulin receptor alternative splicing is associated with insulin resistance in myotonic dystrophy. Nat Genet 2001;29: 40-7.
20. Paul S, Dansithong W, Kim D, Rossi J, Webster NJ, Comai L, et al. Interaction of muscleblind, CUG-BP1 and hnRNP H proteins in DM1- associated aberrant IR splicing. EMBO J 2006;25: 4271-83.
21. Talukdar I, Sen S, Urbano R, Thompson J, Yates JR III, Webster NJ. hnRNP A1 and hnRNP F modulate the alternative splicing of exon 11 of the insulin receptor gene. PLoS One 2011;6: e27869.
22. Blivet-Van Eggelpoel MJ, Chettouh H, Fartoux L, Aoudjehane L, Barbu V, Rey C, et al. Epidermal growth factor receptor and HER-3 restrict cell response to sorafenib in hepatocellular carcinoma cells. J Hepatol 2012;57: 108-15.
23. Podevin P, Carpentier A, Pene V, Aoudjehane L, Carriere M, Zaidi S, et al. Production of infectious hepatitis C virus in primary cultures of human adult hepatocytes. Gastroenterology 2010;139: 1355-64.
24. Schiffer E, Housset C, Cacheux W, Wendum D, Desbois-Mouthon C, Rey C, et al. Gefitinib, an EGFR inhibitor, prevents hepatocellular carcinoma development in the rat liver with cirrhosis. Hepatology 2005;41: 307-14.
25. Corpechot C, Barbu V, Wendum D, Chignard N, Housset C, Poupon R, et al. Hepatocyte growth factor and c-Met inhibition by hepatic cell hypoxia: a potential mechanism for liver regeneration failure in experimental cirrhosis. Am J Pathol 2002;160: 613-20.
26. Desbois-Mouthon C, Danan C, Amselem S, Blivet-Van Eggelpoel MJ, Sert-Langeron C, Goossens M, et al. Severe resistance to insulin and insulin-like growth factor-I in cells from a patient with leprechaunismas a result of two mutations in the tyrosine kinase domain of the insulin receptor. Metabolism 1996;45: 1493-500.
27. Bertrand F, Atfi A, Cadoret A, L'Allemain G, Robin H, Lascols O, et al. A role for nuclear factor kappaB in the antiapoptotic function of insulin. J Biol Chem 1998;273: 2931-8.
28. Berasain C, Castillo J, Prieto J, Avila MA. New molecular targets for hepatocellular carcinoma: the ErbB1 signaling system. Liver Int 2007; 27: 174-85.
29. Castillo J, Erroba E, Perugorria MJ, Santamaria M, Lee DC, Prieto J, et al. Amphiregulin contributes to the transformed phenotype of human hepatocellular carcinoma cells. Cancer Res 2006;66: 6129-38.
30. Cui H, Wu F, Sun Y, Fan G, Wang Q. Up-regulation and subcellular localization of hnRNP A2/B1 in the development of hepatocellular carcinoma. BMC Cancer 2010;10: 356.
31. Baffy G, Brunt EM, Caldwell SH. Hepatocellular carcinoma in nonalcoholic fatty liver disease: an emerging menace. J Hepatol 2012;56: 1384-91.
32. Leclercq IA, Da Silva Morais A, Schroyen B, Van Hul N, Geerts A. Insulin resistance in hepatocytes and sinusoidal liver cells: mechanisms and consequences. J Hepatol 2007;47: 142-56.
33. Desbois-Mouthon C, Baron A, Blivet-Van Eggelpoël M, Fartoux L, Venot C, Bladt F, et al. IGF-1R inhibition induces a resistance mechanism via the EGFR/HER3/AKT signaling pathway: rational basis for co-targeting IGF-1R and EGFR in hepatocellular carcinoma. Clin Cancer Res 2009;15: 5445-56.
34. Blanquart C, Achi J, Issad T. Characterization of IRA/IRB hybrid insulin receptors using bioluminescence resonance energy transfer. Biochem Pharmacol 2008;76: 873-83.
35. Borlak J, Meier T, Halter R, Spanel R, Spanel-Borowski K. Epidermal growth factor-induced hepatocellular carcinoma: gene expression profiles in precursor lesions, early stage and solitary tumours. Oncogene 2005;24: 1809-19.
36. Abu Dayyeh BK, Yang M, Fuchs BC, Karl DL, Yamada S, Sninsky JJ, et al. A functional polymorphism in the epidermal growth factor gene is associated with risk for hepatocellular carcinoma. Gastroenterology 2011;141: 141-9.
37. Tanabe KK, Lemoine A, Finkelstein DM, Kawasaki H, Fujii T, Chung RT, et al. Epidermal growth factor gene functional polymorphism and the risk of hepatocellular carcinoma in patients with cirrhosis. JAMA 2008;299: 53-60.
38. Perugorria MJ, Latasa MU, Nicou A, Cartagena-Lirola H, Castillo J, Goni S, et al. The epidermal growth factor receptor ligand amphiregulin participates in the development of mouse liver fibrosis. Hepatology 2008;48: 1251-61.
39. Moon WS, Park HS, Yu KH, Park MY, Kim KR, Jang KY, et al. Expression of betacellulin and epidermal growth factor receptor in hepatocellular carcinoma: implications for angiogenesis. Hum Pathol 2006;37: 1324-32.
40. Yeh MM, Larson AM, Campbell JS, Fausto N, Rulyak SJ, Swanson PE. The expression of transforming growth factor-alpha in cirrhosis, dysplastic nodules, and hepatocellular carcinoma: an immunohistochemical study of 70 cases. Am J Surg Pathol 2007;31: 681-9.
41. Reinehr R, Haussinger D. Epidermal growth factor receptor signaling in liver cell proliferation and apoptosis. Biol Chem 2009;390: 1033-7.
42. Castillo J, Goni S, LatasaMU, Perugorria MJ, Calvo A, Muntane J, et al. Amphiregulin induces the alternative splicing of p73 into its oncogenic isoform DeltaEx2p73 in human hepatocellular tumors. Gastroenterology 2009;137: 1805-15.
43. Honore B, Baandrup U, Vorum H. Heterogeneous nuclear ribonucleoproteins F and H/H' show differential expression in normal and selected cancer tissues. Exp Cell Res 2004;294: 199-209.
44. Wang GL, Salisbury E, Shi X, Timchenko L, Medrano EE, Timchenko NA. HDAC1 promotes liver proliferation in young mice via interactions with C/EBPbeta. J Biol Chem 2008;283: 26179-87.
45. Zhou ZJ, Dai Z, Zhou SL, Fu XT, Zhao YM, ShiYH, et al. Overexpression ofHnRNPA1 promotes tumor invasion through regulating CD44v6 and indicates poor prognosis for hepatocellular carcinoma. Int J Cancer 2013;132: 1080-9.
46. Sen S, Jumaa H, Webster NJ. Splicing factor SRSF3 is crucial for hepatocyte differentiation and metabolic function. Nat Commun 2013;4: 1336.
47. Karni R, de Stanchina E, Lowe SW, Sinha R, Mu D, Krainer AR. The gene encoding the splicing factor SF2/ASF is a proto-oncogene. Nat Struct Mol Biol 2007;14: 185-93.
48. Dauksaite V, Akusjarvi G. Human splicing factor ASF/SF2 encodes for a repressor domain required for its inhibitory activity on pre-mRNA splicing. J Biol Chem 2002;277: 12579-86.
49. Ghigna C, Giordano S, Shen H, Benvenuto F, Castiglioni F, Comoglio PM, et al. Cell motility is controlled by SF2/ASF through alternative splicing of the Ron protooncogene. Mol Cell 2005;20: 881-90.
50. Sanford JR, Coutinho P, Hackett JA, Wang X, Ranahan W, Caceres JF. Identification of nuclear and cytoplasmic mRNA targets for the shuttling protein SF2/ASF. PLoS One 2008;3: e3369.